PMID- 25138425
OWN - NLM
STAT- MEDLINE
DCOM- 20150421
LR  - 20160303
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 136
IP  - 7
DP  - 2015 Apr 1
TI  - Haploidentical hematopoietic stem cell transplantation in adults with 
      Philadelphia-negative acute lymphoblastic leukemia: no difference in the high- 
      and low-risk groups.
PG  - 1697-707
LID - 10.1002/ijc.29146 [doi]
AB  - Allogeneic hematopoietic stem cell transplantation (HSCT) is the most effective 
      post-consolidation therapy and curative option for adult patients with 
      Philadelphia chromosome-negative (Ph-negative) acute lymphoblastic leukemia (ALL) 
      in first complete remission (CR1). A human leukocyte antigen (HLA)-haploidentical 
      related donor (haplo-RD) is one of the most important alternative sources for 
      those without HLA-identical sibling donor (ISD). The present study aimed to 
      evaluate the outcomes of haploidentical hematopoietic stem cell transplantation 
      (haplo-HSCT) in adult Ph-negative ALL CR1 patients (n = 183). We produced an 
      unmanipulated haplo-HSCT protocol including granulocyte colony stimulating factor 
      (G-CSF) for all donors, intensive immune suppression, anti-thymocyte globulin, 
      and combination of G-CSF-primed bone marrow harvest and G-CSF-mobilized 
      peripheral blood stem cells harvest as the source of stem cell grafts. The median 
      age for high-risk versus low-risk groups were 29 versus 23 years. Three-year 
      incidences of relapse mortality and nonrelapse mortality for high-risk versus 
      low-risk groups were 7.1% versus 11.1% (p = 0.498) and 18.0% versus 16.2% 
      (p = 0.717), respectively. Three-year probabilities of disease-free survival and 
      overall survival for high-risk versus low-risk groups were 67.6% versus 68.2% 
      (p = 0.896) and 74.9% versus 72.7% (p = 0.981), respectively. Multivariate 
      analysis showed that limited cGVHD and a lower pre-HSCT comorbidity burden were 
      associated with better outcomes. In summary, comparable outcomes were observed 
      among high- and low-risk Ph-negative ALL CR1 patients after haplo-HSCT. Haplo-RD 
      could be considered for adults with Ph-negative ALL in CR1 as an important 
      alternative source of donors in cases when no ISD is available.
CI  - (c) 2014 UICC.
FAU - Mo, Xiao-Dong
AU  - Mo XD
AD  - Peking University People's Hospital & Peking University Institute of Hematology, 
      Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, No. 11 
      Xizhimen South Street, Xicheng District, Beijing, 100044, China.
FAU - Xu, Lan-Ping
AU  - Xu LP
FAU - Zhang, Xiao-Hui
AU  - Zhang XH
FAU - Liu, Dai-Hong
AU  - Liu DH
FAU - Wang, Yu
AU  - Wang Y
FAU - Chen, Huan
AU  - Chen H
FAU - Yan, Chen-Hua
AU  - Yan CH
FAU - Chen, Yu-Hong
AU  - Chen YH
FAU - Han, Wei
AU  - Han W
FAU - Wang, Feng-Rong
AU  - Wang FR
FAU - Wang, Jing-Zhi
AU  - Wang JZ
FAU - Liu, Kai-Yan
AU  - Liu KY
FAU - Huang, Xiao-Jun
AU  - Huang XJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140902
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Female
MH  - Graft Survival
MH  - Graft vs Host Disease/etiology
MH  - HLA Antigens/genetics
MH  - *Haplotypes
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Histocompatibility Testing
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Philadelphia Chromosome
MH  - Precursor Cell Lymphoblastic 
      Leukemia-Lymphoma/diagnosis/*genetics/mortality/*therapy
MH  - Recurrence
MH  - Risk Factors
MH  - Transplantation Chimera
MH  - Transplantation, Homologous
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - Philadelphia-negative acute lymphoblastic leukemia
OT  - adult
OT  - haploidentical
OT  - hematopoietic stem cell transplantation
EDAT- 2014/08/21 06:00
MHDA- 2015/04/22 06:00
CRDT- 2014/08/21 06:00
PHST- 2014/07/15 00:00 [received]
PHST- 2014/08/06 00:00 [revised]
PHST- 2014/08/08 00:00 [accepted]
PHST- 2014/08/21 06:00 [entrez]
PHST- 2014/08/21 06:00 [pubmed]
PHST- 2015/04/22 06:00 [medline]
AID - 10.1002/ijc.29146 [doi]
PST - ppublish
SO  - Int J Cancer. 2015 Apr 1;136(7):1697-707. doi: 10.1002/ijc.29146. Epub 2014 Sep 
      2.